From: Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study
Risk factor | Number of cases (% of all individuals treated) |
---|---|
GU tract pathology (stones, cancer of prostate/bladder/kidneys, urethral disease, self catheterisation) | 25 (33.3) |
Renal transplant | 12 (16.0) |
Systemic disease (non-renal tract malignancy, steroids, diabetes, cardiovascular disease, GI tract disease) | 12 (16.0) |
Pregnant | 3 (4.0) |
No documented risk factor(s) a | 23 (30.7) |
TOTAL | 75 |